Allarity Therapeutics, Inc. financial data

Symbol
ALLR on Nasdaq
Industry
Pharmaceutical Preparations
Location
24 School St., 2 Nd Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 51.2 % +40.2%
Debt-to-equity 848 %
Return On Equity -644 % -129%
Return On Assets -67.9 % +26.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.4M shares +1453%
Common Stock, Shares, Outstanding 35M shares +6858%
Entity Public Float 3.32M USD -68.6%
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 15M shares +80342%
Weighted Average Number of Shares Outstanding, Diluted 15M shares +80342%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.8M USD +20.4%
General and Administrative Expense 9.12M USD +0.24%
Operating Income (Loss) -16.9M USD +11.6%
Nonoperating Income (Expense) 1.74M USD -1.91%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.63M USD +31.6%
Income Tax Expense (Benefit) -4K USD
Net Income (Loss) Attributable to Parent -11.6M USD +14.4%
Earnings Per Share, Basic 499 USD/shares +100%
Earnings Per Share, Diluted 6.85K USD/shares +100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.2M USD +4479%
Other Assets, Current 131K USD -91.2%
Assets, Current 21.3M USD +478%
Property, Plant and Equipment, Net 17K USD -34.6%
Operating Lease, Right-of-Use Asset 6K USD -93%
Intangible Assets, Net (Excluding Goodwill) 9.71M USD -24.2%
Assets 30.9M USD +130%
Accounts Payable, Current 7.75M USD -4.15%
Accrued Liabilities, Current 1.47M USD -23.7%
Liabilities, Current 10.6M USD -16.2%
Deferred Income Tax Liabilities, Net 432K USD +25.9%
Liabilities 11M USD -21.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -530K USD +20.4%
Retained Earnings (Accumulated Deficit) -99.9M USD -13.2%
Stockholders' Equity Attributable to Parent 19.8M USD
Liabilities and Equity 30.9M USD +130%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.49M USD +53.5%
Net Cash Provided by (Used in) Financing Activities 1.38M USD +19.2%
Net Cash Provided by (Used in) Investing Activities 809K USD
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 35M shares +6858%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.04M USD +58.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.2M USD +4479%
Interest Paid, Excluding Capitalized Interest, Operating Activities 9K USD -30.8%
Deferred Tax Assets, Valuation Allowance 16.8M USD +26.1%
Deferred Tax Assets, Gross 16.3M USD +26.1%
Operating Lease, Liability 8K USD -92.5%
Depreciation 23K USD -58.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -11.5M USD +11.8%
Operating Lease, Liability, Current 8K USD -91.8%
Deferred Income Tax Expense (Benefit) -14K USD
Deferred Tax Assets, Operating Loss Carryforwards 17M USD +30.6%
Preferred Stock, Shares Issued 1.42K shares
Additional Paid in Capital 120M USD +45.6%
Preferred Stock, Shares Outstanding 1.42K shares
Depreciation, Depletion and Amortization 23K USD -58.9%
Share-based Payment Arrangement, Expense -22K USD -112%
Interest Expense 508K USD +84.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares